Biosimilars pipeline report: A guide for understanding the growing market

By Sean McGowan

Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. To date, there have been 32 approvals and 21 launches in the U.S. biosimilar market. As this market matures, its pipeline continues to grow.

This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market. 

Enter your information to access the latest biosimilar pipeline report






By submitting this form, I hereby consent to the receipt of marketing materials from AmerisourceBergen and its affiliates via email and other forms of communications.


About the Author

Sean McGowan

Senior Director, Biosimilars
View Bio